# Pizarra — PT-pseudo_d7d26761c714 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d7d26761c714
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 7.7 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.03 ng/mL/yr
  - Prior PSA: 4.6 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6079056 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7.7 ng/mL. PI-RADS 3. PSAD 0.11. Prostate volume 73 mL. csPCa 0.61.

Vitals: weight 86 kg, height 177 cm, BMI 27.5, BP 120/82 mmHg, HR 80 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to prior histological confirmation of malignancy and a recent PSA rise to 7.7 ng/mL.

History: At 64 years of age, this mechanical engineer entered surveillance protocols after a positive biopsy established ISUP Grade Group 1 carcinoma. Residing on an operational agricultural property alongside his spouse, his daily routine entails early hours and intermittent manual tasks, yet he characterizes his general mobility as largely sedentary with sporadic strolls. Lower urinary tract complaints are entirely absent, reflected by an IPSS score of 1. He explicitly denies haematuria, pelvic discomfort, or osseous pain. Cardiovascular parameters remain stable under valsartan and metoprolol therapy, a combination maintained for years. A minor knee arthroscopy performed in his late forties constitutes his sole surgical history, alongside a mild visual deficit necessitating large-print reading materials. Alcohol intake averages four units per week, and documented allergies remain absent. His long-standing companion acts as his designated next of kin. He abstains from tobacco entirely.

Physical examination: DRE — glandular assessment: symmetrically enlarged, uniformly smooth with firm consistency, devoid of discrete nodules or contour irregularities. General inspection: well-nourished adult, appearing comfortable without acute distress. Auscultation confirms clear pulmonary fields and a regular cardiac rhythm measuring 80 beats per minute. Vascular pressure registers 120/82 mmHg. Lower extremities show no pitting oedema, and lymphatic chains remain non-palpable.

Patient info: mechanical engineer; Married; Lives on a working farm with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 1/35 (mild LUTS).


Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.48 +/- 0.19   (95% CI 0.12-0.85)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=3.0, psa=7.7, age=64.0, psad=0.11, dre_ord=0.0, vol=73.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS 3, PSA 7.7, prior positive biopsy) and failed to weigh the critical context provided by the retrieved documents, specifically the PSA velocity (1.03 ng/mL/yr), the prior PSA (4.6 ng/mL), and the specific risk stratification derived from the PSA density (0.11 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested 'NO BIOPSY' with a wide uncertainty interval (0.48 +/- 0.19). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. This is problematic because the clinical situation involves a rising PSA (from 4.6 to 7.7) following a prior positive diagnosis, which is a key clinical driver that the prior ignored.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes
The retrieval of the PSA history and laboratory panel would allow for a more precise risk assessment regarding the PSA density and velocity, which is crucial for applying the guideline matrix.

GUIDELINE ANCHOR
The guideline search indicates that the decision depends on a risk-adapted matrix linking PI-RADS score, PSA-D categories, and PSA levels. Specifically, the prevalence of ISUP GG $\ge 2$ cancer varies significantly across these categories, suggesting that the specific values for PI-RADS 3 and PSA-D 0.11 ng/mL² must be used to guide the decision.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d7d26761c714", "radiology_report": "Subject: Prostate Multiparametric MRI | Facility: Antoni van Leeuwenhoek Hospital | Date: 29 December 2024\nClinical Indication:\nFollow-up assessment for established malignancy. Current serum PSA measures 7.7 ng/mL. Previous histopathology confirmed ISUP Grade Group 1 disease.\nFINDINGS:\nThe gland exhibits a total volume of 73.0 mL, displaying symmetrical enlargement alongside uniform T2 weighting throughout the peripheral compartments. A discrete region of intermediate signal intensity occupies the left mid-gland peripheral zone, spanning roughly 12 x 10 mm. Diffusion-weighted imaging and ADC mapping reveal mild restriction within this focus, devoid of associated T2 signal loss. Dynamic contrast sequences demonstrate an absence of definitive early or sustained enhancement. Extracapsular dissemination and seminal vesicle infiltration remain unobserved. Pelvic lymph nodes appear normal, and skeletal structures show no metastatic foci.\nIMPRESSION:\nDiscrete abnormality localized to the left mid-gland peripheral compartment, assigned PI-RADS 3.\nCalculated PSA density: 0.11 ng/mL/mL.\nEstimated csPCa probability: 0.6079056"}
get_psa_trend
{"case_id": "PT-pseudo_d7d26761c714", "psa_trend": [{"date": "Dec 2022", "val": 5.3}, {"date": "Dec 2023", "val": 5.1}, {"date": "Jan 2025", "val": 7.7}]}
get_previous_notes
{"case_id": "PT-pseudo_d7d26761c714", "previous_notes": [{"date": "09 Jan 2024", "author": "Dr. F. de Boer (GP)", "text": "Initial consultation occurred after an elevated PSA reading of 6.0 ng/mL was recorded in late 2022. A repeat measurement in December 2023 indicated a decline to 4.6 ng/mL. Given the patient\u2019s age alongside the previously confirmed histological diagnosis, an mpMRI was scheduled and a referral to the urology outpatient department was submitted. Hypertension remains adequately managed with valsartan and metoprolol."}, {"date": "08 May 2024", "author": "Dr. F. de Boer (GP)", "text": "Subsequent visit addressed the urology referral pathway. The individual has completed imaging and pathological evaluation, with all documentation filed accordingly. Systemic health status remains stable, and the prescribed pharmacological regimen continues unchanged."}]}
get_lab_results
{"case_id": "PT-pseudo_d7d26761c714", "laboratory_results": [{"name": "PSA", "val": "7.7 ng/mL", "date": "07 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.93 ng/mL", "date": "07 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "07 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.2 g/dL", "date": "07 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.4 x10^9/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "236 x10^9/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "99 umol/L", "date": "07 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "07 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "10.4 nmol/L", "date": "07 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "89 U/L", "date": "07 Dec 2024", "flag": ""}, {"name": "LDH", "val": "193 U/L", "date": "07 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.5 %", "date": "07 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The specific ISUP grade group or Gleason score of the prior biopsy was not explicitly documented in the retrieved documents, only that it was ISUP Grade Group 1.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity: 1.03 ng/mL/yr (Rising trend from 4.6 to 7.7 ng/mL).
- MRI finding: Discrete abnormality localized to the left mid-gland peripheral compartment (PI-RADS 3).

AGAINST sampling this patient now:
- Prior biopsy result: ISUP Grade Group 1 carcinoma.
- MRI finding: Lesion is localized and PI-RADS 3, suggesting low-to-intermediate risk.

WHERE THIS LEANS
The rising PSA velocity and the presence of a new, albeit low-risk, lesion on MRI suggest a need for further characterization, leaning towards a recommendation for biopsy to re-evaluate the risk profile.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior diagnosis of ISUP Grade Group 1 carcinoma, the rising PSA velocity of 1.03 ng/mL/yr from 4.6 to 7.7 ng/mL, combined with the PI-RADS 3 finding on MRI, suggests the need for further characterization. The statistical prior suggested no biopsy, but the retrieved PSA trend and the presence of a new lesion on MRI tipped the balance toward re-evaluation. Therefore, a biopsy is recommended to re-evaluate the risk profile given the PSA trajectory.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
